In my last post, I introduced the Choosing Wisely™ campaign, an effort by clinicians to avoid overuse or inappropriate use of tests and therapies. Obviously, a successful campaign would save lots of money. But the campaign is motivated by a higher goal that reflects the mission of Healthy Survivorship.
Continue reading "Choosing Wisely Campaign - Part II" »
Did you know that when you take a generic drug, you essentially forfeit the ability to sue the company making the drug for damages if you experience an adverse event?
Continue reading "Problems with Generics" »
In my last post, I asked, "Why not, at least, make Avastin available to breast cancer patients who are doing well on it?"
Continue reading "Revoking FDA Approval: Right or Wrong? - Part IX" »
Now let's look at the players who influenced the FDA's decision to revoke approval of Avastin for breast cancer. The complex process requires a book-length manuscript to fully explain. Rather than abandon my effort, here are the bare bones:
Continue reading "Revoking FDA Approval: Right or Wrong? - Part V" »
My last post provided an outline of the FDA's approval process. I cringed while writing it, knowing 250 words couldn't capture the investment of time, people and capital.
Continue reading "Revoking FDA Approval: Right or Wrong? - Part IV" »
In my November 28th and December 3rd posts I introduced the media storm regarding the FDA's recent revocation of approval of Avastin for the treatment of breast cancer. Today I'll provide an overview of the FDA approval process to help us talk about the controversy.
Continue reading "Revoking FDA Approval: Right or Wrong - Part III" »
Recently the FDA revoked approval of a best-selling drug, Avastin, for treatment of breast cancer. Ever since, arguments for and against the removal have been voiced in blogs and major media by a wide variety of people with different points of view. Let's look at some of the issues in the context of Healthy Survivorship.
Continue reading "Revoking FDA Approval: Right or Wrong?" »
My recent posts have discussed some of the difficulties of modern medical decision-making in the context of PSA testing for prostate cancer. A new book by Harvard oncologist Jerome Groopman and Harvard endocrinologist Pamela Hartzband offers help to Healthy Survivors: Your Medical Mind: How to Decide What is Right for You.
Continue reading "Your Medical Mind" »
My August 6th post shares a report on a new technology for breast cancer screening. I confess: I did not check out the story.
Continue reading "My Bad?" »
Effective communication is an essential element of Healthy Survivorship. So I felt honored when MD Anderson Cancer Center's Dr. Walter Baile invited me to write and narrate an audiovisual module titled TALKING ABOUT SIDE EFFECTS OF CANCER TREATMENTS
Continue reading "Talking About Side Effects of Cancer Treatments" »
In my last post, Hope or Letting Go, I shared the story of a physician, Dr. Youn, still troubled by an incident that happened ten years ago. Since reading it, I've been bothered by some of the questions he posed.
For example, Dr. Youn asked if concern for the needs of the patient's loved ones ever take precedence over the patients' needs?
Continue reading "Hope or Letting Go - Part II" »
Patients are not Healthy Survivors if they believe the promises of charlatans. What about patients who receive treatment from of team of professionals at a major university in a clinical trial that turns out to be based on wrong information?
Continue reading "From Promise to Disaster" »
We are not born knowing how to become Healthy Survivors. We aren't taught in school how to get good care and live as fully as possible when living with, through and beyond cancer or other serious illness. I wish we were.
Continue reading "Free Toolbox" »
If a picture is worth a thousand words, this 17-minute video by Eric Slade Productions is worth at least an undecillion (1 followed by 36 zeros).
Continue reading "Understanding Post-Treatment Survivorship" »
In 2006, leaders in the state of Washington created the Health Technology Assessment (HTA) program to evaluate the cost-effectiveness of various medical therapies. With our country facing a huge budget deficit, what could be better than determining which treatments are worth paying for?
Continue reading "The Pro-Diabetes Board" »
My recent posts are about the trouble of defining "rare cancers." The attention these cancers are now getting gives Healthy Survivors many reasons for hope.
Continue reading "Rare Cancer Initiatives" »
A common complaint about modern medicine is the depersonalization of the patient and the loss of compassion." So let's take a look at compassion.
Continue reading "Compassion in Modern Medicine" »
I chose internal medicine as a career because I love having "the big picture."
One of my great concerns about the changes in modern medicine is this: It is becoming increasingly common for none of the clinicians on a patient's healthcare team to have that big picture so vital to expert and compassionate care.
Continue reading "The Big Picture" »
I shudder when I hear stories of physicians who order a CT scan to evaluate a patient's pain without examining the painful area. So I was happy to read that Dr. Abraham Verghese is on a mission to save the art of the physical exam.
Continue reading "Bringing Back the Physical Exam" »
On my recent post about clinical trials, commenter Steve Walker wrote, "The Phase III trial is being run primarily to satisfy the rigid, formulaic and in many cases scientifically obsolete requirements imposed by the FDA's Office of Oncology Drug Products for most cancer drugs...."
Is the randomized clinical/controlled trial (RCT) obsolete?
Continue reading "Abigail's Alliance" »
Recently, I've pointed out the clashes between business and ethical considerations and beween clinicians' obligations to their individual patients and to the method that leads to advances. What if researchers can find ways to satisfy both the science and today's patients?
Continue reading "Testing a Fast Track to Rx" »
In Phase I trials researchers test an experimental treatment in a few patients for the first time. The purpose is NOT to see if the treatment kills cancer cells, but only to:
- evaluate the drug's safety
- determine a safe dosage range
- identify side effects
What if the patients in a Phase I trial experience shrinkage of their tumors? Should this speed up FDA approval of the trial drug?
Continue reading "The Problem with Accelerated FDA Approval" »
My last post introduced a dilemma regarding modern clinical trials: Is it ethical to randomize some patients to the "control arm" of a trial where they will NOT receive the trial drug?
According a NYTimes article, one particular trial of a therapy (called PLX4032) for malignant melanoma "ignited an anguished debate among oncologists about whether a controlled trial that measures a drug's impact on extending life is still the best method for evaluating hundreds of genetically targeted cancer drugs being developed."
Continue reading "Anguished Debate on Witholding Rx for the Control Arm" »
People who hear my story often say, "You had an advantage getting into those clinical trials, because you were a doctor with connections." Given the paucity of patient-centered resources in 1993, this was true.
Today a plethora of excellent resources can help patients and families learn about clinical trials and find any available trials that might be right for you. Resources include:
Continue reading "Researching Clinicial Trials" »
As a scientist, I credit clinical trials with advancing our understanding of cancer and ability to treat it effectively. As a patient, I credit clinical trials with playing an essential role in my survival.
From both perspectives it troubles me greatly that only ~3% of adult cancer patients participate in clinical trials.
Continue reading "The Treatment Option You May Be Missing" »
For me, the crux of the problem is this: Do open notes conflict with the ideal of compassionate care?
Continue reading "Open Notes and Compassionate Care" »
My recent posts set the stage for asking: Does the opportunity for patients to read their medical charts help or hurt patients' ability to become Healthy Survivors?
Continue reading "Open Notes: "Our" Chart" »
In my August 9th post, I introduced you to the OpenNotes project. If you are wondering why we need the study, here is a two-word answer: informational technology.
Continue reading "The OpenNotes Project - Why Do We Need It?" »
Have you ever read what your physicians and nurses have written in your medical chart? If not, would you want to?
For the next few posts, we'll explore the OpenNotes project in the context of Healthy Survivorship.
Continue reading "The OpenNotes Project - Introduction" »
Great progress has been made in linking disease to mutations in certain genes. So why the sudden brouhaha at the FDA about companies selling gene-testing kits directly to consumers?
Continue reading "Caveat Emptor re: Genetic Testing" »
In the newsletter of the Texas Chapter of the American College of Physicians, Dr. Steve Urban shares an important concern about Electronic Health Records (EHR).
Continue reading "A Problem with the Electronic Health Record (EHR)" »
What a three days I've had here at the 2010 Biennial Conference. While packing my suitcase for the return home, I'm thinking about all I've heard.
Continue reading "Cancer Survivorship Research: Recovery and Beyond" »
Tomorrow begins a conference entitled "Cancer Survivorship Research: Recovery and Beyond." And I have a job to do.
Continue reading "Wendy in Washington" »
I've been following a provocative blog, Musings of a Distractable Mind, hosted by primary care physician Dr. Rob Lamberts. His recent post entitled "10 Rules for Good Medicine." offers food for thought about modern healthcare. Here is a sampling, with my commentary added:
Continue reading "10 Rules for Good Medicine" »
Your doctors evaluate your pain and conclude it is due to something benign (i.e., you don't have cancer, a broken bone or other health-threatening condition). Then they give you a prescription for a placebo. Should you sue these doctors? Or thank them?
Continue reading "Placebos -- The Magic Cure" »
The task sounds innocent enough: You copy your medical records on your personal home copier or an office copier, making sure nobody is looking over your shoulder and making sure to take all your originals and copies with you. Are you safe? Maybe not.
Continue reading "Copying Off Your Privacy" »
After being diagnosed with a disease, many Healthy Survivors ask, "Do I need to see a specialist to get good care?"
Continue reading "Do I Need a Specialist?" »
Will someone please explain this to me: Clinical trials are the modern tool for finding truths about preventing and treating cancer. Yet our system puts obstacles in the path of clinicians who might participate in designing and running trials and in the path of patients who might enroll in trials.
Continue reading "Calling all Patients!" »
You were introduced to Dr. Bradford Berk on my Feb 19th post, The Comeback Physician. I'm happy to share the update reported in the current Rochester Review: Berk is Back.
Let me draw your attention to one of Dr. Berk's key messages:
Continue reading "Berk is Back" »
Patients obtain medical information not only from their healthcare team but also from the Internet. Time Magazine's Bonnie Rochman discusses one potential benefit of this phenomenon in a fascinating article entitled, "When Patients Share Medical Data Online."
Continue reading "Patient 2.0 " »
We've been discussing the importance of valuing the time it takes primary care physicians to listen to their patients.
Continue reading "Listening to Patient's Stories" »
What does it mean to "value" the time and expertise of primary care clinicians (PCPs)?
Continue reading "Valuing PCPs" »
In yesterday's post I explained why combining college and med school into six years is not a good antidote to the primary care shortage (in my opinion). Here are other ideas that might help encourage medical students to go into primary care:
Continue reading "Addressing the Primary Care Shortage" »
The author of a recent post on YJHM (the companion blog for the Yale Journal for Humanities in Medicine) suggested that combining college and med school into six years is a good idea as an antidote to the primary care shortage.
I, too, am concerned about the growing shortage of primary care clinicians. But this idea worries me.
Continue reading "Antidote for Primary Care Shortage" »
Huh? CISCRP? Is that a word?
No, it is the acronym for a non-profit organization I'd like to highlight. Then you'll have it in the back pocket of your brain in case you ever need it for yourself or someone you love.
Continue reading "CISCRP" »
Yesterday I spoke to pre-health and pre-law students at
UTD who are taking a "Law & Medicine" course. What did I say in my hour?
Continue reading "Lessons for Undergrads" »